Welcome!

News Feed Item

Human Reproductive Technologies: Products and Global Markets

LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

STUDY GOALS AND OBJECTIVES

The objective of the study is to present a comprehensive, up-to-date look at the market for reproductive technologies and products. Markets are divided according to treatment type and indication. The products in some markets are mature, while products in other markets are just beginning to emerge. The report is directed to decision-makers in the various areas of reproductive drugs and technologies, and it provides insight into those arenas for current and future development.

REASONS FOR STUDY

This BCC Research study is presented to increase the awareness of the global reproductive market by identifying pharmaceutical preparations, devices, technologies and important advancements within the industry. The study analyzes the new therapeutics and technologies for reproductive health and it addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and technologies have stepped up discovery, as the engine driving growth in all markets is research and development.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.

• Infertility market—male and female factors, pharmaceuticals and future advancements.
o IVF.
o Assistive reproductive technologies.
o Fertility diagnostics.
• Contraception—pharmaceuticals and devices.
• Sexual dysfunction—pharmaceuticals and devices.

Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on extensive, first-hand interviews with primary executives, product managers and clinical specialists in the area of reproductive health. Random surveying provided information about the use of products and how products are obtained. Background information was obtained from various government and business sources, medical journals, and trade magazines and interviews with doctors. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in reproductive drugs and technologies in healthcare. Interviews were also used to confirm and/or adjust market size and competitor market share estimates, as well as to formulate market projections.

All market data pertain to the global market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year is 2013; historical data are provided for 2011 and 2012 and forecast data are provided for 2018. Historical, base year and forecast data are provided for each market segment and subsegment. Market share information is provided for each market subsegment for the 2013 base year.

All average annual growth rates are estimated based on the compilation of data, which includes estimated prevalence of conditions, population growth, products in research and development, historical trends, patent expirations and generic competition.

INTENDED AUDIENCE

This report was prepared as a study of the human reproductive technologies marketplace. Information is presented on the human reproductive technologies industry in general, pharmaceuticals and devices, new technology within the market, new and novel drug applications and market-related issues; in many cases actual revenue is given for the period of 2011 and 2012, with projections of trends and compound annual growth rates (CAGRs) from 2013 through 2018.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives. It also will be of interest to biologists and those interested in the field of reproductive technologies.

ANALYST CREDENTIALS

Mary Anne Crandall is a Medical Analyst, specializing in the pharmaceuticals industry for 20 years, currently working on a Ph.D. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry.

REPORT HIGHLIGHTS

The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.

This report provides:

• An overview of the market for human reproductive technologies.
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examinations of market sizes in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception, and sexual dysfunction, with a division of markets according to treatment type and indication.
• Evaluations of pipeline products and technologies.
• Patent analysis.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR STUDY 2
SCOPE OF STUDY 2
METHODOLOGY AND INFORMATION SOURCES 3
INTENDED AUDIENCE 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS) 7
SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS) 7

CHAPTER 3 INDUSTRY OVERVIEW 9

STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM 9
MALE 9
FEMALE 10
Neuroendocrine Regulation 13
Menarche 14
Menstruation Cycle 14
PHASES OF SEXUAL RESPONSES 15
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
Male Sexual Response 16
Female Sexual Response 16
NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE
SYSTEM 17
Estrogen 18
Progestogens 18
Testosterone 19
EFFECTS OF AGING 19
ISSUES AND TRENDS OF REPRODUCTIVE HEALTH 21
CONTRACEPTIVE INSURANCE 21
OVER-THE-COUNTER BIRTH CONTROL PILLS 21
PREIMPLANTATION GENETIC DIAGNOSIS 22
DESIGNER BABIES 22
NEW USE FOR CONTRACEPTIVES 24
AGING AND INFERTILITY 25
DEATH BY CONTRACEPTIVE PATCH 26
SEXUAL DYSFUNCTION AND CANCER 27
INFERTILITY AND CANCER 28
Chemotherapy 28
Radiation 29
Prevention Strategies 30
Procreative Alternatives 30
SIGNALING PATHWAY FOR FERTILITY TREATMENT 31
MARKETING TACTICS 31
MALE BIRTH CONTROL 32
MERCHANDISING TARGETING WOMEN 32
COUNTERFEIT PRODUCTS 32
SURPLUS EMBRYOS AND FETUSES 33
STEM CELL AND OTHER CONTROVERSIAL ISSUES - SELECTED
INTERNATIONAL VIEWS 35
CONTROVERSIAL DISPOSAL OF EMBRYOS 39
DEMOGRAPHICS 41
UNITED STATES 41
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST
YEAR: 2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
EU 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
ASIA 47

CHAPTER 4 INFERTILITY MARKET 50

INTRODUCTION AND OVERVIEW OF INFERTILITY 50
DEFINITION OF INFERTILITY 50
ETIOLOGY OF INFERTILITY 50
EVALUATION OF FERTILITY 50
Male Factor 51
Artificial Insemination 52
Vaginal and Cervical Factors 55
Immunological Factors 56
Uterine and Tubal Factors 57
Ovarian Factors 58
UNEXPLAINED INFERTILITY 59
MULTIPLE BIRTHS 60
ASIA FACTOR 61

CHAPTER 5 METHODS OF TREATMENT 63

FERTILITY PHARMACEUTICALS 63
INTRODUCTION AND TYPES 63
Antagon 64
Bravelle 65
Cetrotide 65
Clomid 65
Crinone and Prometrium 66
Fertinex 67
Follistim 67
Gonal-F 67
Humegon 68
Lupron 68
Novarel 68
Ovidrel 69
Parlodel 69
Pregnyl 69
Profasi 69
Prometrium 69
Repronex 69
Serophene 70
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
MARKET REVENUES AND FORECAST 71
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
FUTURE ADVANCEMENTS IN INFERTILITY PRODUCTS 72
CORIFOLLITROPIN ALFA INJECTION 72
PROGESTERONE VAGINAL RING 72
XM17 72
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
COMPETITIVE ANALYSIS 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73

CHAPTER 6 ASSISTIVE REPRODUCTIVE TECHNOLOGIES 75

INTRODUCTION 75
TYPES 75
IVF 75
Ovulation Induction 76
Oocyte Retrieval 76
Intracytoplasmic Sperm Injection (ICSI) 76
Fertilization 77
Embryo Transfer 77
Results of IVF 77
GIFT 78
ZIFT 78
WOMBS FOR RENT 79
OOCYTE DONATION 80
FROZEN EMBRYOS 81
UNITED STATES FERTILITY CLINICS 82
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011
(%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
INTERNATIONAL FERTILITY CLINICS 84
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
MARKET REVENUES AND FORECAST 85
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
FUTURE TRENDS IN ASSISTIVE REPRODUCTIVE TECHNOLOGY 85
COMPETITIVE ANALYSIS 87
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87

CHAPTER 7 FERTILITY DIAGNOSTICS 90

INTRODUCTION 90
TYPES 90
Urine Studies 90
Pregnancy Testing 90
Ovulation Testing 91
Sperm Testing 92
Hormone Studies 93
Blood Studies 93
MARKET REVENUES AND FORECAST 94
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
COMPETITIVE ANALYSIS 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FUTURE ADVANCEMENTS IN DIAGNOSTIC FERTILITY TREATMENT 95
TOTAL INFERTILITY MARKET REVENUES AND FORECAST 96
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96

CHAPTER 8 CONTRACEPTION MARKET 98

INTRODUCTION AND OVERVIEW OF CONTRACEPTION 98
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
PHARMACEUTICALS 101
Types 101
Oral Contraceptives 101
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
Alesse 105
Beyaz 105
Brevicon and Norinyl 105
Desogen 105
Estrostep 105
Levlen ED 106
Levora 106
Lo -Loestrin 106
Lo/Ovral 106
Low-Ogestrel 106
Lybrel 106
Microgestin 107
Mircette 107
Natazia 107
Necon 107
Nordette 107
Nor-QD 107
Ortho Evra 108
Ortho Micronor 108
Ortho Tri-Cyclen 108
OrthoCept 108
Ovcon 35 109
Ovral 109
Quartette 109
Safyral 109
Seasonale 109
Tri-Levlen 110
Tri-Norinyl 110
Triphasil 110
Trivora 110
Yasmin 28 110
Zovia 111
Zoely 111
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
OTHER DRUG REGIMENS FOR CONTRACEPTION 114
Depo-Provera 114
Plan B One Step 114
Mifeprex 115
MARKET REVENUES AND FORECAST 115
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
COMPETITIVE ANALYSIS 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
PRESCRIPTION DEVICES 117
INTRODUCTION AND TYPES 117
Intrauterine Devices 118
NuvaRing 118
Implanon 119
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
MARKET REVENUES AND FORECAST 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
COMPETITIVE ANALYSIS 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FUTURE ADVANCEMENTS IN CONTRACEPTION 121
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
AG-200-15 122
ARC 122
C31G (SAVVY) 122
FC PATCH 122
LECETTE 122
AG890 123
USHERCELL 123
LEVOSERT IUD 123
TOTAL MARKET REVENUES AND FORECAST 123
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124

CHAPTER 9 SEXUAL DYSFUNCTION MARKET 126

INTRODUCTION AND OVERVIEW 126
TYPES OF SEXUAL DYSFUNCTION 126
CAUSES OF SEXUAL DYSFUNCTION 127
DEMOGRAPHICS OF SEXUAL DYSFUNCTION 127
PHARMACEUTICALS 128
Introduction and Types 128
Viagra 128
Cialis 128
Levitra 128
Staxyn 129
Stendra/Spendra 129
Yohimbine 129
Caverject 129
MUSE 129
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
MARKET REVENUES AND FORECAST 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
COMPETITIVE ANALYSIS 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
DEVICES 132
Introduction and Types 132
SomaTherapy-ED SOMAerect Stf 132
Viberect 133
Erectaid Classic System 133
AMS Inflatable Penile Implant 134
Coloplast Titan OTR 134
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
MARKET REVENUES AND FORECAST 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
COMPETITIVE ANALYSIS 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION 136
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
Flibanserin 137
Femprox 137
LibiGel 137
Lybrido and Lybridos 137
Tefina 138
Topiglan 138
Zoraxel 138
Zydena (udenafil) 138
TOTAL MARKET REVENUES AND FORECAST 138
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139

CHAPTER 10 PATENTS 141

PATENT ANALYSIS BY MANUFACTURER 141
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
PATENTS BY APPLICATION 141
INFERTILITY TREATMENTS 141
CONTRACEPTION 142
SEXUAL DYSFUNCTION 142

CHAPTER 11 LEADING MARKET MANUFACTURERS 144

TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144

CHAPTER 12 TOTAL MARKET 147

TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TOTAL GLOBAL MARKET FOR REPRODUCTIVE TECHNOLOGIES AND PRODUCTS
BY REGION 147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
TOTAL MARKET SIZE BY CATEGORY 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER
OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY
MARKET SEGMENT, 2013 ($ MILLIONS/%)
151
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
INDUSTRY PARTICIPANTS BY CATEGORY 152
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TOTAL MARKET SIZE BY PRODUCT TYPE 154
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

CHAPTER 13 PARTICIPATING COMPANIES 157

COMPANY PROFILES 157
ACTAVIS, INC 157
BAYER AG 157
BRISTOL-MYERS SQUIBB CO. 159
CHURCH & DWIGHT COMPANY INC. 159
COOPERSURGICAL INC. 159
ELI LILLY & CO. 160
EMD SERONO, INC 160
FERRING PHARMACEUTICALS 161
GLAXOSMITHKLINE PLC 161
JANSSEN PHARMACEUTICAL 162
MERCK INC. 162
NOVARTIS INTERNATIONAL AG 163
PFIZER INC. 163
PRINCETON BIOMEDITECH CORP. 164
QUIDEL CORP 164
VIVUS INC. 165

CHAPTER 14 APPENDIX A 167

SELECTED LIST OF U.S. FERTILITY CLINICS 167
ALABAMA 167
ARIZONA 167
CALIFORNIA 168
COLORADO 169
CONNECTICUT 170
DISTRICT OF COLUMBIA 170
FLORIDA 170
GEORGIA 171
IDAHO 171
ILLINOIS 171
INDIANA 172
KANSAS 173
MAINE 173
MARYLAND 173
MASSACHUSETTS 173
MICHIGAN 174
MINNESOTA 174
MONTANA 174
NEVADA 174
NEW HAMPSHIRE 175
NEW JERSEY 175
NEW YORK 176
NORTH CAROLINA 176
OREGON 176
RHODE ISLAND 177
SOUTH CAROLINA 177
SOUTH DAKOTA 177
TEXAS 177
UTAH 178
VIRGINIA 178
WASHINGTON 178
SELECTED LIST OF FERTILITY CLINICS IN OTHER REGIONS 179
ASIAN FERTILITY CLINICS 179
AUSTRIA 180
Innsbruck 180
Vienna 180
SWITZERLAND 181
Basel 181
Geneva 181
Zurich 182
GERMANY 182
FRANCE 183
Paris 183
ITALY 183
Naples 183
Rome 184
GREAT BRITAIN 184
London 184

CHAPTER 15 APPENDIX B: LIST OF COMPANIES 187

TABLE 51 LIST OF COMPANIES 187

LIST OF TABLES

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS)
7
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR:
2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144
TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF
MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET
SEGMENT, 2013 ($ MILLIONS/%)
151
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
TABLE 51 LIST OF COMPANIES 187

LIST OF FIGURES

SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS)
7
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

Read the full report:
Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that EARP will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "We are a software house, so we perfectly understand challenges that other software houses face in their projects. We can augment a team, that will work with the same standards and processes as our partners' internal teams. Our teams will deliver the same quality within the required time and budget just as our partn...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
SYS-CON Events announced today that Tappest will exhibit MooseFS at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. MooseFS is a breakthrough concept in the storage industry. It allows you to secure stored data with either duplication or erasure coding using any server. The newest – 4.0 version of the software enables users to maintain the redundancy level with even 50% less hard drive space required. The software func...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Systena America will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Systena Group has been in business for various software development and verification in Japan, US, ASEAN, and China by utilizing the knowledge we gained from all types of device development for various industries including smartphones (Android/iOS), wireless communication, security technology and IoT serv...
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
DevOps at Cloud Expo – being held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real r...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...